Validation of five prognostic models treated with axitinib beyond first-line nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma: a Japanese multicenter retrospective study.
Kikuchi H, Osawa T, Matsushita Y, Kojima T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Ueda K, Tanaka H, Kurahashi T, Bando Y, Kimura T, Nishiyama N, Kato T, Hara H, Ito Y, Kitamura H, Miyake H, Shinohara N.
Kikuchi H, et al. Among authors: ueda k.
Jpn J Clin Oncol. 2025 Feb 2:hyaf018. doi: 10.1093/jjco/hyaf018. Online ahead of print.
Jpn J Clin Oncol. 2025.
PMID: 39893579